Engine Biosciences to Decipher Genetic Codes for Drug Discovery with $43 Million Round
Engine Biosciences, a company deciphering complex biology to unleash impactful therapeutics plans to use funds from a $43 million funding
Read moreEngine Biosciences, a company deciphering complex biology to unleash impactful therapeutics plans to use funds from a $43 million funding
Read moreThe European Commission has approved Astellas’ XTANDI™ (enzalutamide) for men with metastatic Hormone-Sensitive Prostate Cancer (mHSPC). Japanese multinational pharmaceutical company
Read moreEvotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) revealed that it has invested in OxVax, a new immuno-oncology organization
Read moreBristol-Myers Squibb is investing in a brand new cell therapy facility which will be located at the Leiden Bio Science
Read moreIrish pharmaceutical company Shorla Pharma Limited (‘Shorla’), has reported that it has successfully filed a priority review application for its
Read moreHistoSure, in cooperation with Charles River Discovery Research Services Germany, now offers a set of groundbreaking highly validated species-specific antibodies
Read moreThe European Commission (EC) has approved Sarclisa® (isatuximab) in combination with carfilzomib and dexamethasone (Kd) for the treatment of adult
Read moreEctica Technologies is delighted to announce it will be presenting as a corporate sponsor at the upcoming CHI Conference on
Read moreFrench pharma giant Sanofi is set to acquire Tidal Therapeutics for $470m, adding the biotech’s novel mRNA-based research platform with
Read moreBristol Myers Squibb announced positive results from a Phase 3 Trial, which showed that neoadjuvant treatment with three cycles of
Read more